Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNA-polyethylenimine idiotypic vaccine
- Development stage
- Unknown
- Lead developer
- Belarusian Research Center for Pediatric Oncology Hematology and Immunology
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
**DNA-polyethylenimine idiotypic vaccine** is a personalized therapeutic cancer vaccine designed for patients with B-cell non-Hodgkin lymphoma. It consists of a plasmid DNA encoding a patient-specific single-chain variable fragment (scFv) or idiotype, fused to an immunostimulatory gene (either potato virus X coat protein [PVXCP] or human chemokine MIP3α), and is delivered as a complex with linear polyethylenimine (PEI, synthetic polymer, commonly 8 or 20 kDa) to enhance in vivo transfection and antigen expression. The vaccine aims to elicit both humoral and cellular immune responses by improving DNA uptake and presenting lymphoma-specific antigens. Phase I trials have reported endpoints of safety, tolerability, and immunogenicity in several histological subtypes of B-cell non-Hodgkin lymphoma[1][2][3][5].
- Other names
- idiotypic DNA vaccine administered as a complex with polyethylenimineDNA-PEI idiotypic vaccineDNA-polyethylenimine idiotypic vaccine
02
Targets
Id (Tumor-specific idiotype immunoglobulin)CP (Ceruloplasmin)
Beyond the preview
Go deeper on DNA-polyethylenimine idiotypic vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNA-polyethylenimine idiotypic vaccine.